Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

Addition of Blinatumomab to Consolidation Therapy Among Older Newly Diagnosed Patients (pts) with BCR::ABL1 Negative B-Lineage Acute Lymphoblastic Leukemia (ALL) in the ECOG-ACRIN E1910 Randomized Phase III Trial

Blood (2024) 144 (Supplement 1): 4211.

https://doi.org/10.1182/blood-2024-207143

Published: 2024

Journal Articles

Assessment of Outcomes of Allogeneic Stem Cell Transplantation By Treatment Arm in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia Randomized to Conventional Chemotherapy +/- Blinatumomab in the ECOG-ACRIN E1910 Phase III National Clinical Trials Network Trial

Blood (2024) 144 (Supplement 1): 779.

https://doi.org/10.1182/blood-2024-207557

Published: 2024

Journal Articles

Assessment of Outcomes of Consolidation Therapy By Number of Cycles of Blinatumomab Received in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia: In the ECOG-ACRIN E1910 Randomized Phase III National Clinical Trials Network Trial

Blood (2023) 142 (Supplement 1): 2877.

https://doi.org/10.1182/blood-2023-189648

Published: 2023

Journal Articles

A Phase 1b/2 Trial of Liposomal Cytarabine and Daunorubicin (CPX-351) in Intermediate to High-Risk Acute Myeloid Leukemia for Patients Who Have Failed an Initial Cycle of Induction Chemotherapy

Blood (2023) 142 (Supplement 1): 5946.

https://doi.org/10.1182/blood-2023-184344

Published: 2023

Journal Articles

Consolidation Therapy with Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients with B-Lineage Acute Lymphoblastic Leukemia in Measurable Residual Disease Negative Remission: Results from the ECOG-ACRIN E1910 Randomized Phase III National Cooperative Clinical Trials Network Trial

Blood (2022) 140 (Supplement 2): LBA-1.

https://doi.org/10.1182/blood-2022-171751

Published: 2022

Journal Articles

Patterns of Neuropathy in ALL Patients Treated with Vincristine Based Regimens with and without Tyrosine Kinase Inhibitors

Audrey M. Sigmund, Michelle Fullmer, Rina Li, Tracelyn Freeman, Bryant Clemons, Stefanie Quimjian, Heather Niccum Haag, Ai Ni, Shuiying Hu, Alice S. Mims, Gretchen A. McNally, Maryam Lustberg, Bhavana Bhatnagar

Blood (2022) 140 (Supplement 1): 5180–5182.

https://doi.org/10.1182/blood-2022-166961

Published: 2022

Journal Articles

Effect of High Intensity Chemotherapy Vs Targeted Therapy on Survival in AML Patients Aged 60-75

Kieran D Sahasrabudhe, Melanie T Rebechi, Ying Huang, Greg K. Behbehani, Bhavana Bhatnagar, James S. Blachly, Bradley W Blaser, Uma Borate, Ramiro Garzon, Tamanna Haque, Karilyn Larkin, Meixiao Long, Alice S. Mims, Ayman Saad, Sumithira Vasu, Alison R. Walker, Sarah A Wall

Blood (2021) 138 (Supplement 1): 4125.

https://doi.org/10.1182/blood-2021-148676

Published: 2021

Journal Articles

Gilteritinib Can be Safely Combined with Atezolizumab for the Treatment of Relapsed or Refractory FLT3 -Mutated AML: Results of a Phase 1 Study

Jessica K. Altman, Bhavana Bhatnagar, Sameem Abedin, Amanda Przespolewski, Prapti A. Patel, Gary J. Schiller, Stanley Gill, Dhruva Patel, Linyi Fan, Ramon V. Tiu, Stephen A. Strickland

Blood (2021) 138 (Supplement 1): 2343.

https://doi.org/10.1182/blood-2021-150707

Published: 2021

Journal Articles

Aspacytarabine (BST-236) As Monotherapy Is Safe, Well-Tolerated and Effective for the Treatment of Adults with Newly Diagnosed Acute Myeloid Leukemia Unfit for Intensive Therapy. Results of a Phase 2 Study

Blood (2021) 138 (Supplement 1): 1273.

https://doi.org/10.1182/blood-2021-149361

Published: 2021

Journal Articles

High-Dimensional Analysis Identifies Mechanisms of Gilteritinib Resistance in FLT3 -Mutated AML

Daelynn R Buelow, Bhavana Bhatnagar, Jae Yoon Jeon, Megan Zavorka Thomas, Eric Eisenmann, Jack Stromatt, Shelley Orwick, Navjot Pabla, James S. Blachly, Sharyn Baker, Bradley W Blaser

Blood (2021) 138 (Supplement 1): 207.

https://doi.org/10.1182/blood-2021-148569

Published: 2021

Journal Articles

Non-Relapse Mortality in TP53 -Mutated MDS/AML - a Multi-Center Collaborative Study

Blood (2021) 138 (Supplement 1): 2922.

https://doi.org/10.1182/blood-2021-154151

Published: 2021

Journal Articles

Updated Efficacy of Eltanexor Monotherapy in Patients with Higher Risk Hypomethylating Myelodysplastic Syndrome Primary Refractory to Hypomethylating Agents

Sangmin Lee, Sanjay R Mohan, Jessica Knupp, Kamal Chamoun, Igor Karasik, Vicky Xiang Bai, Kimberly Ingalls, Fan Yang, Jatin J. Shah, Michael G. Kauffman, Sharon Shacham, Bhavana Bhatnagar

Blood (2021) 138 (Supplement 1): 3676.

https://doi.org/10.1182/blood-2021-151359

Published: 2021

Journal Articles

Post-Traumatic Stress Disorder (PTSD) Symptoms in Patients with Acute Myeloid Leukemia (AML)

Hermioni L. Amonoo, MD, Areej El-Jawahri, MD, Thomas W. LeBlanc, MDMA,MS, Alison R. Kavanaugh, NP, Jason A. Webb, MD, Lara Traeger, PhD, Annemarie D. Jagielo, BA, Dagny M. Vaughn, MS, Madeleine Elyze, BA, Regina M. Longley, BA, Amir T. Fathi, Gabriela S. Hobbs, MD, Andrew M. Brunner, Nina R. O'Connor, MD, Selina M. Luger, MD FRCPC, Jillian Gustin, MD, Bhavana Bhatnagar, DO, Nora K. Horick, MS

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-133857

Published: 2020

Journal Articles

A Phase I Clinical Trial Testing the Safety of IL-21-Expanded, Off-the-Shelf, Third-Party Natural Killer Cells for Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Sumithira Vasu, MDMBBS, Bhavana Bhatnagar, DO, James S. Blachly, MD, Nicole Szuminski, BS, Lynn O'Donnell, PhD, Dean Anthony Lee, MD PhD

Blood (2020) 136 (Supplement 1): 44.

https://doi.org/10.1182/blood-2020-139170

Published: 2020

Journal Articles

Psychological Distress in Young Adults with Acute Myeloid Leukemia Undergoing Induction Chemotherapy

Bethany Lockwood, MD, Areej El-Jawahri, MD, Alison R. Walker, MD, Deborah Russell, FNP-BC,ACHPN, Jillian Gustin, MD, Sarah Ehrman, MD, Seuli Bose-Brill, MD, Maryam Lustberg, MD, Bhavana Bhatnagar, DO

Blood (2020) 136 (Supplement 1): 17–18.

https://doi.org/10.1182/blood-2020-140589

Published: 2020

Journal Articles

Poor Treatment Outcomes of Young (<60 Years) African American Patients (Pts) Diagnosed with Acute Myeloid Leukemia (AML) (Alliance)

Blood (2020) 136 (Supplement 1): 5–7.

https://doi.org/10.1182/blood-2020-140999

Published: 2020

Journal Articles

Durable Remissions and Increased Overall Survival in AML Patients Deemed Unfit for Standard Intensive Chemotherapy Achieved with High-Dose BST-236 (Aspacytarabine) Induction and Consolidation

Jessica K. Altman, MD, Selina M. Luger, MD FRCPC, Olga Frankfurt, MD, Tsila Zuckerman, MD, Jamie L. Koprivnikar, MD, Vamsi Kota, MD, Ashkan Emadi, MD, PhD, Bhavana Bhatnagar, DO, Dale L. Bixby, MD, Micah M. Burch, MD, Ofir Wolach, MD, Itai Levi, MD, Anna Gourevitch, MD, Ron Ram, MD, Liat Flaishon, PhD MD, Shoshi Tessler, PhD, Stela Gengrinovitch, PhD, Ruth Ben Yakar, PhD, Jacob M. Rowe, MB, BS

Blood (2020) 136 (Supplement 1): 9–10.

https://doi.org/10.1182/blood-2020-139136

Published: 2020

Journal Articles

Multi-Site Randomized Trial of Integrated Palliative and Oncology Care for Patients with Acute Myeloid Leukemia (AML)

Areej El-Jawahri, MD, Thomas W. Leblanc, Alison R. Kavanaugh, NP, Jason A. Webb, MD, Vicki Jackson, MD, Toby Campbell, MD, Nina R. O'Connor, MD, Selina M. Luger, MD FRCPC, Ellin Gafford, MD, Jillian Gustin, MD, Bhavana Bhatnagar, DO, Amir T. Fathi, MD, Gabriela S. Hobbs, MD, Showly Nicholson, BS, Debra Davis, Jennifer S. Temel

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-138883

Published: 2020

Journal Articles

Factors Associated with High Healthcare Utilization at the End-of-Life (EOL) for Patients with Acute Myeloid Leukemia

Dagny M. Vaughn, MS, P. Connor Johnson, MD, Annemarie D. Jagielo, BA, Matthew J. Reynolds, BA, Alison R. Kavanaugh, NP, Jason A. Webb, MD, Amir T. Fathi, MD, Gabriela S. Hobbs, MD, Andrew M. Brunner, MD, Nina R. O'Connor, MD, Selina M. Luger, MD FRCPC, Bhavana Bhatnagar, DO, Thomas W. LeBlanc, MDMA,MS, Areej El-Jawahri, MD

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-139777

Published: 2020

Journal Articles

NPM1 mutations Using Deep Amplicon Sequencing and Broad Next Generation Sequencing at the Time of Complete Remission Is Informative to Predicting Risk of Relapse Following Intensive Chemotherapy

Bhavana Bhatnagar, DO, Shelley Orwick, BS, Nyla A. Heerema, PhD, Alison R. Walker, MD, Alice S. Mims, MD, James S. Blachly, MD, Karilyn Larkin, MD, Nicole Grieselhuber, MD PhD, Gregory K. Behbehani, MD PhD, Apollinaire Ngankeu, Charles Thomas Gregory, BS, John C. Byrd, MD

Blood (2019) 134 (Supplement_1): 1329.

https://doi.org/10.1182/blood-2019-130856

Published: 2019

NARROW

Addition of Blinatumomab to Consolidation Therapy Among Older Newly Diagnosed Patients (pts) with BCR::ABL1 Negative B-Lineage Acute Lymphoblastic Leukemia (ALL) in the ECOG-ACRIN E1910 Randomized Phase III Trial

Assessment of Outcomes of Consolidation Therapy By Number of Cycles of Blinatumomab Received in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia: In the ECOG-ACRIN E1910 Randomized Phase III National Clinical Trials Network Trial

A Phase 1b/2 Trial of Liposomal Cytarabine and Daunorubicin (CPX-351) in Intermediate to High-Risk Acute Myeloid Leukemia for Patients Who Have Failed an Initial Cycle of Induction Chemotherapy

Consolidation Therapy with Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients with B-Lineage Acute Lymphoblastic Leukemia in Measurable Residual Disease Negative Remission: Results from the ECOG-ACRIN E1910 Randomized Phase III National Cooperative Clinical Trials Network Trial

Patterns of Neuropathy in ALL Patients Treated with Vincristine Based Regimens with and without Tyrosine Kinase Inhibitors

Effect of High Intensity Chemotherapy Vs Targeted Therapy on Survival in AML Patients Aged 60-75

Gilteritinib Can be Safely Combined with Atezolizumab for the Treatment of Relapsed or Refractory FLT3 -Mutated AML: Results of a Phase 1 Study

Aspacytarabine (BST-236) As Monotherapy Is Safe, Well-Tolerated and Effective for the Treatment of Adults with Newly Diagnosed Acute Myeloid Leukemia Unfit for Intensive Therapy. Results of a Phase 2 Study

High-Dimensional Analysis Identifies Mechanisms of Gilteritinib Resistance in FLT3 -Mutated AML

Non-Relapse Mortality in TP53 -Mutated MDS/AML - a Multi-Center Collaborative Study

Updated Efficacy of Eltanexor Monotherapy in Patients with Higher Risk Hypomethylating Myelodysplastic Syndrome Primary Refractory to Hypomethylating Agents

Post-Traumatic Stress Disorder (PTSD) Symptoms in Patients with Acute Myeloid Leukemia (AML)

A Phase I Clinical Trial Testing the Safety of IL-21-Expanded, Off-the-Shelf, Third-Party Natural Killer Cells for Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Psychological Distress in Young Adults with Acute Myeloid Leukemia Undergoing Induction Chemotherapy

Poor Treatment Outcomes of Young (<60 Years) African American Patients (Pts) Diagnosed with Acute Myeloid Leukemia (AML) (Alliance)

Durable Remissions and Increased Overall Survival in AML Patients Deemed Unfit for Standard Intensive Chemotherapy Achieved with High-Dose BST-236 (Aspacytarabine) Induction and Consolidation

Multi-Site Randomized Trial of Integrated Palliative and Oncology Care for Patients with Acute Myeloid Leukemia (AML)

Factors Associated with High Healthcare Utilization at the End-of-Life (EOL) for Patients with Acute Myeloid Leukemia

NPM1 mutations Using Deep Amplicon Sequencing and Broad Next Generation Sequencing at the Time of Complete Remission Is Informative to Predicting Risk of Relapse Following Intensive Chemotherapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only